Celgene Corporation (NASDAQ:CELG) ~ Initial Phase III Results of the FIRST® Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (PTS) Ineligible for Stem Cell Transplantation (SCT) Accepted for Plenary Presentation at ASH Annual Meeting

[Business Wire] – Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation today announced that data from FIRST® , its phase III study of REVLIMID® in combination with dexamethasone in patients newly diagnosed . . . → Read More: Celgene Corporation (NASDAQ:CELG) ~ Initial Phase III Results of the FIRST® Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (PTS) Ineligible for Stem Cell Transplantation (SCT) Accepted for Plenary Presentation at ASH Annual Meeting Similar posts: Celgene Corporation (NASDAQ:CELG) – Oral Apremilast Demonstrated Clinically Meaningful and Statistically Significant Improvements in Enthesitis and Dactylitis Revealed: The Holy Grail of Stem Cell Research Jury’s Not Out on Stem Cell Research